^
    Back
    Association details:
    Biomarker:BCL2 amplification
    Cancer:Diffuse Large B Cell Lymphoma
    Regimen: (Rituxan (rituximab) + cyclophosphamide + doxorubicin hydrochloride + prednisone + vincristine)
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: C3 – Early Trials
    Source:
    Cancer Biol Med
    Title:

    Prognostic value of BCL2 and TP53 genetic alterations for diffuse large B-cell lymphoma patients treated with R-CHOP

    Published date:
    11/23/2021
    Excerpt:
    Importantly, patients who harbored BCL2 gain/amplifications (BCL2GA/AMP) also had a remarkably inferior 5-year PFS (11.1% vs. 38.3%; P < 0.001) and OS (22.1% vs. 69.6%; P = 0.009)....Multivariable analyses showed that the presence of BCL2 alterations, especially BCL2GA/AMP, TP53 mutations, and International Prognostic Index (IPI) were significantly associated with inferior PFS and OS....This study showed that DLBCL patients treated with R-CHOP, BCL2 alterations, especially BCL2GA/AMP and TP53 mutations were significantly associated with inferior outcomes, which were independent of the IPI.
    DOI:
    10.20892/j.issn.2095-3941.2021.0193
    Evidence Level:
    Resistant: C3 – Early Trials
    Source:
    ASH 2018
    Title:

    Clinical and Biological Features behind Hallmark Aberrations in Diffuse Large B-Cell Lymphoma

    Published date:
    11/01/2018
    Excerpt:
    ...152 primary DLBCL patients treated with R-CHOP or R-CHOP-like regimen....In the ABC/non-GCB DLBCLs, BCL2 copy number aberrations were associated with poor survival independent of IPI (Figure 1B).
    DOI:
    10.1182/blood-2018-99-117958